Class & Mechanism
5-amino-1MQ is an inhibitor of the enzyme nicotinamide adenine dinucleotide methyltransferase (NNMT), which is involved in adipose metabolism. By inhibiting NNMT, 5-amino-1MQ potentially alters the metabolism of nicotinamide adenine dinucleotide (NAD+) and impacts energy metabolism in adipose tissue, leading to changes in fat cell function and potentially weight loss.
Research-documented benefits
Local corpus: silent.
General-knowledge benefits
– Inhibition of NNMT may lead to changes in NAD+ metabolism and energy homeostasis in adipose tissue [1].
– Potentially useful for treating obesity and related metabolic disorders by modulating adipose tissue function [2].
– May improve insulin sensitivity and other metabolic parameters associated with adiposity [3].
Typical injectable protocol
5-amino-1MQ is typically administered via subcutaneous injection. The exact dosing protocol is not well-established due to its experimental nature, but it is generally administered in the microgram range, with treatment cycles lasting several weeks to months. The protocol would need to be individualized based on the patient's response and tolerance to the therapy.
Key risks / contraindications
– As a peptide targeting adipose tissue metabolism, there may be risks of local inflammation and tissue damage at the injection site.
– Systemic effects of NNMT inhibition, such as changes in NAD+ metabolism, could potentially lead to metabolic complications.
– Contraindicated in patients with a history of pancreatitis or other conditions that may be exacerbated by adipose tissue manipulation.
Bottom line
5-amino-1MQ is an experimental peptide with potential applications in the treatment of obesity and related metabolic disorders. Its use is currently investigational, and further research is needed to establish its safety and efficacy profile.
References
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- Basal Insulin Glargine 100 U_mL Versus 300 U_mL in Type 2 Diabetes
- Contemporary Diagnosis and Management of Obesity
- From rapalogs to anti-aging formula
- GLP-1 Receptor Agonists in Type 2 Diabetes
- GLP-1 and the kidney_ from physiology to pharmacology and outcomes in diabetes
- Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
- Handbook of Clinical Nutrition and Aging
- Hazzard's Geriatric Medicine and Gerontology
- Hormone Therapy in Cancer and Aging-related Disorders
- Human trials exploring anti-aging medicines — Guarente, Leonard (author)
- Incretin-Based Therapies for Type 2 Diabetes
- Incretin-Based Therapy_ From Human Physiology to Clinical Treatment
- Kosmetik für Ärzte und Apotheker
- Metabolic Syndrome_ Underlying Mechanisms and Drug Therapies
- Neurocritical Care
- Nutrition in Mental Health_ A Handbook
- Peptide Protocols Volume One — William A Seeds MD
- Pharmacology
- Pituitary Disorders
- Platelets
- Pulmonary Diseases and Disorders
- Super Agers An Evidence-Based Approach to Longevity — Eric Topol
- Surgical Oncology_ Evidence-Based Approaches
- Surgical versus medical therapy of prolactinomas
- Textbook of Natural Medicine
- The AI Revolution in Medicine_ GPT-4 and Beyond
- The discovery and development of liraglutide and semaglutide
- The role of bile acids in the pathophysiology and treatment of type 2 diabetes
- Two incretin hormones, GIP and GLP-1_ similarities and differences